Cargando…
Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial
Chronic low back pain (LBP) is a common condition, usually with the involvement of nociceptive and neuropathic pain components, high economic burden and impact on quality of life. Cebranopadol is a potent, first-in-class drug candidate with a novel mechanistic approach, combining nociceptin/orphanin...
Autores principales: | Christoph, Annette, Eerdekens, Marie-Henriette, Kok, Maurits, Volkers, Gisela, Freynhagen, Rainer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761752/ https://www.ncbi.nlm.nih.gov/pubmed/28644196 http://dx.doi.org/10.1097/j.pain.0000000000000986 |
Ejemplares similares
-
Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic
por: Kleideiter, Elke, et al.
Publicado: (2017) -
Correction to: Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic
por: Kleideiter, Elke, et al.
Publicado: (2018) -
Cebranopadol: A First-in-Class Nociceptin Receptor Agonist for Managing Chronic Pain
por: Nair, Abhijit S, et al.
Publicado: (2020) -
Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study
por: Göhler, Karin, et al.
Publicado: (2019) -
Mixed-methods development of a new patient-reported outcome instrument for chronic low back pain: part 2—The Patient Assessment for Low Back Pain–Impacts (PAL-I)
por: Bushnell, Donald M., et al.
Publicado: (2018)